VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Kjell Thörnbring has been appointed to the new CEO of Artimplant AB. He has been acting CEO since May 4 and he has at the same time maintained the position of CFO. Kjell Thörnbring has a B.Sc in Business Administration from the Gothenburg University and he has previously had leading positions as CEO and CFO in public Swedish companies.
The following changes have also been implemented in Artimplant´s management group:
Susan Linke has been appointed to Financial Manager. She has been employed by the company since 2007. Susan has earlier been an accountant in the company and she has previously a background as Financial Manager.
Hanna Stenhamre has been appointed to manage the new department Clinical Affairs. Hanna has been employed by Artimplant since 2005 and she has been responsible for preclinical research. Hanna holds a MSc from Chalmers University of Technology and she also holds a PhD in biomaterial science from the Gothenburg University. The department of Clinical Affairs is responsible for clinical studies and clinical documentation and it will have a close cooperation with the marketing and sales department.
”Artimplant has during a long period of time had profitability problems and we has had difficulties to achieve set objectives. In connection with the annual shareholder´s meeting a new Board of Directors was elected and a new CEO has now been appointed. In a close cooperation the Board of Directors and the Management revise the company's activities in order to identify any problems and to take necessary measures in order to create a competitive and profitable company,” says the Chairman of Artimplant Anders Cedronius.
Västra Frölunda, June 28, 2011
Chairman of the Board
Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal.
Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis in hands and feet, shoulder and other soft tissue injuries as well as oral and veterinary applications. The Company's products are sold through licensees and own sales under Artimplant’s brand take place through agents and distributors.
Artimplant is a public company listed on the NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on June 28 2011 at 10AM (CET).
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Reg. No. 556404-8394
This information was brought to you by Cision http://www.cisionwire.com